Three decades of progress in the therapy of human hypertension, fueled by a steady flow of novel pharmacologic agents, have established contemporary pharmacotherapy as broadly effective, safe, and acceptable to patients. Although the selection of specific regimens for individual patients remains a trial-and-error process, the wide range of currently available drugs virtually ensures that skilled clinicians will be able to reduce blood pressure to desired levels in all patients. However, as the number of choices increases, so does the complexity of their application, and many today approach the antihypertensive pharmacopoea with trepidation. This review attempts to provide an overview of the currently available pharmaceuticals, limited to those used in chronic oral therapy, and a description of strategies for their use in contemporary practice.
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I. Oral Agents Marketed for Antihypertensive Therapy
Available agents are summarized in Table 1 . The following comments expand on some of the advantages and potential drawbacks of specific classes.
A. DIURETICS
Diuretics formed the basis of our original "stepped-care" therapy and continue to be the most widely used drugs worldwide. Despite possible disadvantages related to physiological and biochemical side-effects, it must be conceded that diuretics remain remarkably efficacious, affordable, and generally well-tolerated. All the major trials assessing the efficacy of antihypertensive therapy in reducing cardiovascular morbidity and mortality have included a diuretic treatment limb, and no other class of drugs has ever been demonstrated to be superior to diuretics in reducing all-cause mortality. Concerns about the use of diuretics as initial therapy have centered about two issues: 1) the provocation of biochemical side-effects which may be related to adverse outcomes; and 2) the relatively high incidence of subjective side-effects which limit patient acceptance.
Diuretic agents (thiazides, "loop" and indoline) lower blood pressure in hypertensive patients by impairing renal tubular sodium reabsorption through the inhibition of site-specific luminal mem- Group side effects: Similar to thia-DR l-8 zide except that these agents proSide effects are similar for the entire class of thiazide diuretics. Hypokalemia, hyperuricemia, hypomagnesemia, hypercalcemia, azotemia, muscle cramps, weakness, arrhythmias, dizziness, glucose intolerance, impotence. Hypercholesterolemia (increased total, decreased HDL, hypertriglyceridemia.
Hypercholesterolemia
(increased total, decreased HDL), hypertriglyceridemia Peripheral arterial insufficiency, intermittent claudication, Raynaud's phenomenon (through blockade of vasodilator beta,-receptors).
Exacerbation of coronary insufficiency after abrupt withdrawal of betablocker treatment in patients with coronary heart disease.
Postural hypotension, dizziness, gastrointestinal symptoms, bronchqconstriction, depression, lethargy, headache. brane transport systems. Regardless of their site of action along the nephron (the early distal tubule for thiazides, and the thick ascending limb of Henle's loop for "loop" diuretics), diuretics lower blood pressure because of the sodium loss which they produce. During the initiation of chronic diuretic therapy, negative sodium balance is induced, leading to a contraction of plasma and extracellular fluid volumes and a drop in cardiac output. Subsequently, blood volume returns toward normal and cardiac output rises, coincident with a fall in peripheral resistance.
This "resetting" of the peripheral resistance-cardiac output relationship is unexplained but has been attributed to: (1) a decrease in vascular reactivity to pressor stimuli; Reducing sodium intake to approximately 100 mEq per day (4-6 grams of NaCl/ day) lowers blood pressure significantly in approximately 50% of subjects with mild hypertension. Salt restriction also potentiates the antihypertensive effect of diuretic agents and is, in general, a useful adjunct to pharmacotherapy of hypertension.
B. SYMPATHOLYTIC AGENTS
Available agents are best subclassified according to their primary site of action, central or peripheral. It should be recognized that cardioselectivity is only a relative selectivity; that is, given a high enough concentration of drug at either /3-receptor subtype, blockade will occur. Clinically, the degree of cardioselectivity of the agents available is sufficient to offer a useful degree of differential P,-and &-blockade that permits the clinician to ameliorate &-mediated side&effects in a substantial proportion of patients with troubling complaints of mild wheezing, cough, or cold extremities.
Centrally active agents
ISA is the pharmacologic property of partial agonist activity and in current clinical usage refers to drugs having activity at the &-receptor subtype. Since &-receptor antagonists are often structurally quite similar to &-receptor agonists, it has been possible to produce agents which, while competitively antagonizing the effects of endogenous circulating or neuronally released catecholamines, mildly stimulate the receptors they occupy. The net physiologic effect of these drugs thus depends on the prevailing level of P-adrenergic tone and the strength of the partial agonist potency of the drug. In states of high prevailing tone, such as congestive heart failure or dynamic exercise, P-blocking effects (cardioselective or nonselective, depending on the agent) are prominent, and heart rate and cardiac output are lowered. In states of low sympathetic tone, e.g., resting in the supine posture, administration of an agent with ISA may increase heart rate as the partial agonist property is expressed in the absence of endogenous P-adrenergic tone. In general, drugs with ISA support the basal heart rate above that seen with non-ISA &blockers and therefore may be useful in selected patients who develop symptomatic bradycardias on non-ISA &blockers. In addition, P-blockers with ISA seem to cause fewer disturbances in lipid metabolism than those without ISA.
The degree of lipid-or water-solubility of a compound largely dictates its route of elimination from the body and thus has a major impact on pharmacokinetics. Highly lipid-soluble agents are largely metabolized in the liver where biotransformation renders them more water-soluble and facilitates renal and biliary excretion. Since individuals may have widely different hepatic drug metabolizing capacities, plasma levels of highly lipid soluble compounds often vary greatly (20-fold) and unpredictably, necessitating dose titration to ensure adequate pblockade. Since the liver is a very efficient drug metabolizing system, lipid-soluble compounds are generally cleared from the circulation rapidly and consequently have short plasma half-lives. Conversely, renal excretion of drugs is relatively slow and half-lives for water-soluble compounds accordingly long, Although the antihypertensive effects of @blockers are not strictly dependent on maintenance of &blocking plasma concentrations, in general, the longer the plasma half-life, the longer the dosing interval, Thus, the most water-soluble agents (nadolol [ Recently, a sustained-release propranolol preparation (Inderal LA@) has been introduced to allow once daily dosing of that drug.
Currently available agents permit selection of the various combinations of cardioselectivity, ISA and water solubility for particular patient needs. It should be reemphasized that such tailoring of therapy is directed solely toward avoiding side effects and increasing compliance, as all the available /3-blockers have equivalent antihypertensive potency. When a P-blocker is selected as an antihypertensive to take advantage of a related activity, e.g., cardioprotection in the post-myocardial infarction patient, pharmacological differences must be considered, as not all P-blockers manifest the same activity for these non-hypertension indications. Alpha-blocking agents such as phenoxybenzamine (Dibenzylinea) have been available for many years, but were of limited utility because they produced unacceptable physiological side-effects (tachycardia, palpitations, dizziness). These effects resulted from nonselective a-blockade at both cy, and cyZ sites and are less prominent with the available a,-selective agents, prazosin (Minipresm) and terazosin (Hytrina). Selective cr,-blockade antagonizes the effect of circulating or neuronally-released catecholamines at vascular a,-receptors without antagonizing the effect of catecholamines on a,-receptors located on the prejunctional membranes of peripheral sympathetic nerve endings. Stimulation of these c+re-ceptors decreases neurotransmitter output during subsequent nerve discharges, a form of negative feedback control. At sites innervated by sympathetic nerves, but not controlled by postjunctional cy,-receptors, such as the heart with its postjunctional P,-receptors, normal feedback inhibition by a;-receptor activation seems to be effective in controlling the reflex sympathetic activation resulting from the blood pressure-lowering effect of vascular cr,-blockade. Thus, prazosin causes vasodilation without prominent reflex tachycardia. The degree of blood pressure lowering resulting from the administration of prazosin is dependent upon the level of cr-adrenergic tone at the blood vessels, and particularly when such tone is high, as in the sodium-depleted state, profound hypotension may result from the first dose of prazosin. This hypotensive effect, which may be unpredictable, does not routinely occur with subsequent doses, as the cardiovascular system seems to shift to nonadrenergic mechanisms to support blood pressure.
A single agent with both CY,-and nonselective Pblocking properties, labetalol, combines the physiological profiles of the two classes. Like other cyIblockers, labetalol lowers blood pressure acutely by vasodilation while its &blocking properties blunt the tendency to reflex sympathetic stimulation of the heart. The net result is maintenance of cardiac output and heart rate during labelatol therapy, making the drug useful in selected patients intolerant of the negative chronotrophic and inotrophic cardiac effects of other &blockers.
In addition, labeta101 has been demonstrated to be of benefit in lowering blood pressure in certain groups, such as black hypertensives, with relative resistance to the antihypertensive effects of other P-blockers. The main limitations of labetalol seem to be a fairly high incidence of side-effects, notably dizziness and gastrointestinal disturbances, the former being particularly common in diuretic-treated patients.
Vasodilators
Because the hemodynamic lesion of essential hypertension is increased vascular resistance, vasodilation is an attractive antihypertensive mechanism. However, as with the nonselective o-blockers, the physiologic adjustments provoked by early attempts at vasodilator monotherapy proved to be limiting. Palpitations, tachycardia, stimulation of renin and catecholamine secretion, renal salt and water retention and headaches were common side effects of monotherapy with hydralazine (Apresoline@). Vasodilators were therefore relegated to "Step 3" therapy, where they were applied in combination with diuretic and sympatholytic drugs to prevent the expression of the reflex adjustments to vasodilation. In addition to hydralazine, minoxidil ( Although the precise contribution of each action of angiotensin II to the maintenance of hypertension is unclear, blockade of angiotensin II production by ACE1 effectively lowers blood pressure by reducing vascular resistance.
Reflex sympathetic activation is minimal, and in most hypertensives, neither heart rate nor cardiac output is significantly affected by ACE inhibitors, Possible explanations of this blunting of the expected sympathetic response to vasodilation include increased vagal discharge and a "desensitizing" effect of ACE inhibitors at peripheral nerve endings. At present, the precise nature of the interaction of ACE inhibitors and the sympathetic nervous system is incompletely understood, but the drugs are clearly effective and well-tolerated vasodilators. Two ACE inhibitors are currently available, captopril (Capote@') and enalapril (Vasotec@). Both are effective inhibitors of ACE, and the drugs differ only in pharmacokinetic properties and side-effects. Captopril was the first oral ACE inhibitor released in the United States, and was initially regarded as having most promise in severe, resistant hypertensives where it was used in rather high doses (>300 mg) in patients refractory to other agents. Early reports of granulocytopenia and proteinuria associated with captopril limited physician acceptance of the agent, particularly in patients with mild-tomoderate hypertension for whom good therapeutic alternatives existed. Subsequent experience has demonstrated captopril to be generally free of serious side-effects when used at lower doses in subjects free of renal failure, which impairs captopril excretion, and collagen vascular disease, a host factor which seems to predispose patients to granulocytopenia. The observation that suppression of white cell production and the development of proteinuria seem to be similar to effects attributed to a structurally related compound, penicillamine, led to modiftcations of the structure of captopril to remove a free sulphydryl group at one end of the molecule. The first non-sulphydryl ACE inhibitor, enalapril, was recently introduced and has proven to be almost free of penicillamine-like side effects. It should be emphasized that many of the serious adverse effects attributed to captopril in earlier studies were probably related to the high doses of captopril employed, and such effects are rare in the lower dose range currently recommended (Table 1) . Captopril does produce several minor side-effects such as dysgeusia and rash that also may be less frequently seen with enalapril.
Those side effects related to inhibition of angiotensin II production (hypotension, flushing, hyperkalemia) or to decreased bradykinin destruction (cough) are shared by both drugs.
Apart from side effects, the only notable difference between captopril and enalapril is in duration of action. Captopril has a plasma half-life of approximately two hours and is generally dosed twice daily, although recent studies suggest that some patients may be adequately controlled on once daily dosing. Enalapril is an inactive prodrug, which is converted in the liver to an active metabolite, 
II. Recent Trends in Antihypertensive Therapy
The goal of antihypertensive therapy continues to be to lower the blood pressure. The rationale for this approach is the considerable evidence demonstrating reductions in fatal and nonfatal cardiovascular events when blood pressure is lowered with drugs, and it is supposed that spontaneous or nonpharmacologically induced reductions are of similar benefit. Current concerns relate less to whether to lower blood pressure than to how to lower it. Although benefits are already substantial, can we do better for our patients?
The Whether one drug is superior to another as monotherapy is currently hotly debated, although direct comparative trials are rare. Various factors other than efficacy need to be considered in the selection of drugs for control of hypertension, the main ones being symptomatic side effects; biochemical side effects; convenience; and expense of administration.
The quality of life of the patient taking medication is the most important of these. Given comparable efficacy, those antihypertensives which produce the least side effects are to be preferred. The same is true of biochemical side effects: agents which do not alter plasma lipids, serum potassium, plasma glucose or uric acid have an added advantage.
Once-daily dosage and low cost are additional reasons for favoring one drug over another.
A major puzzle is the lack of evidence that drug therapy of hypertension decreases the incidence of coronary heart disease (CHD). Although epidemiologic studies amply document the fact that hypertension is a potent risk factor for CHD, most clinical trials of the value of antihypertensive drug therapy document only decreased morbidity and mortality from stroke with little or no benefit for CHD. This is a major problem, since CHD is by far the most common complication of mild hypertension, and an extremely serious one at that. Although the lack of efficacy against CHD is unexplained, and the possibility exists that positive results would have been observed if the trials had been longer or the treatment more aggressive, there is a persistent concern that beneficial effects of blood pressure reduction may have been nullified by noxious effects of drug therapy such as atherogenic dyslipidemia or hypokalemia.
It should be emphasized that these concerns are purely speculative and not firmly enough grounded to warrant extrapolation to clinical practice. In fact the results of the only large, well-designed trial comparing one class of agents (diuretics) to another (P-blockers) reveal no difference in total cardiovascular complications for the two different treatments: patients treated with &blockers had somewhat fewer CHD events, but more strokes than those treated with diuretics.
The net effect, then, was the same for both pharmacologic interventions.
A prudent approach to the management of hypertension today should include a clear emphasis on nonpharmacologic therapy and the control of CHD risk factors other than elevated blood pressure. The major considerations in pharmacologic management should be efficacy and tolerability; therefore drug therapy must be individualized: the ideal treatment is one that lowers the blood pressure while not interfering with the quality of life of the patient.
